GRI Bio Inc. (GRI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.88 (+2.17%), Market cap $0.00B, P/E ratio 0.06, 52-week low–high $0.20 ~ $5.55.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for b
Financial statements, price targets, institutional (13F) holdings and related news for GRI Bio Inc. are updated in real time on BlackAll Trade.
GRI Bio Inc. trades at $1.88 (+2.17%). Real-time quotes and charts are available on BlackAll Trade.
GRI Bio Inc. has a market cap of about $0.00B. Its P/E ratio is 0.06.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune diso